PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 153 filers reported holding PROGENICS PHARMACEUTICALS IN in Q3 2018. The put-call ratio across all filers is 1.25 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $273,000 | -34.8% | 71,758 | -12.7% | 0.11% | +64.7% |
Q4 2019 | $419,000 | +34.3% | 82,233 | +33.1% | 0.07% | +7.9% |
Q3 2019 | $312,000 | -22.4% | 61,773 | -5.3% | 0.06% | -25.9% |
Q2 2019 | $402,000 | +48.3% | 65,214 | +1.1% | 0.08% | +84.8% |
Q4 2018 | $271,000 | -16.9% | 64,532 | +24.1% | 0.05% | +35.3% |
Q3 2018 | $326,000 | -55.0% | 51,998 | -42.3% | 0.03% | -94.7% |
Q2 2018 | $725,000 | -33.9% | 90,177 | -39.4% | 0.64% | +333.1% |
Q3 2017 | $1,096,000 | +8.4% | 148,929 | 0.0% | 0.15% | -2.0% |
Q2 2017 | $1,011,000 | -7.1% | 148,929 | +29.2% | 0.15% | -22.2% |
Q1 2017 | $1,088,000 | +20.9% | 115,300 | +10.6% | 0.19% | -27.9% |
Q4 2016 | $900,000 | +5.0% | 104,213 | -23.0% | 0.27% | -35.0% |
Q3 2016 | $857,000 | +71.7% | 135,340 | +14.4% | 0.41% | +11.9% |
Q2 2016 | $499,000 | +10.2% | 118,285 | +13.9% | 0.37% | -40.7% |
Q1 2016 | $453,000 | -28.8% | 103,807 | 0.0% | 0.62% | -64.3% |
Q4 2015 | $636,000 | – | 103,807 | – | 1.75% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadfin Capital, LLC | 8,951,169 | $54,871,000 | 3.38% |
Virtus ETF Advisers LLC | 103,807 | $636,000 | 1.75% |
BKS ADVISORS, LLC | 291,150 | $1,785,000 | 0.92% |
Piermont Capital Management Inc. | 363,549 | $2,229,000 | 0.71% |
TUDOR INVESTMENT CORP ET AL | 2,370,760 | $14,532,000 | 0.41% |
SEARLE & CO. | 60,000 | $349,000 | 0.34% |
TURNER INVESTMENTS LLC | 252,785 | $1,550,000 | 0.32% |
RICE HALL JAMES & ASSOCIATES, LLC | 891,672 | $5,466,000 | 0.31% |
Phocas Financial Corp. | 635,333 | $3,895,000 | 0.30% |
TFS CAPITAL LLC | 398,283 | $2,441,000 | 0.26% |